<DOC>
	<DOC>NCT01284582</DOC>
	<brief_summary>Phase 1 Study :Safety, Immunogenicity and Dose response of ATH03, a new vaccine against the cholesterol ester transfer protein (CETP), in healthy male subjects with high density lipoprotein cholesterol (HDLc) blood concentrations equal or below 80 mg/dl.</brief_summary>
	<brief_title>Safety, Immunogenicity and Dose Response of ATH03, a New Vaccine Against the Cholesterol Ester Transfer Protein (CETP)</brief_title>
	<detailed_description>This open-label Phase 1 study will be conducted in three groups of 12 subjects with HDLc blood concentrations equal or below 80 mg/dl at a single study center. 36 subjects will be enrolled.</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy males High density lipoprotein cholesterol (HDLc) blood concentrations equal or below 80 mg/dl Clinically relevant pathological findings</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>CETP</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Cholesterol</keyword>
	<keyword>Inhibition</keyword>
</DOC>